<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05119894</url>
  </required_header>
  <id_info>
    <org_study_id>331-102-00373</org_study_id>
    <nct_id>NCT05119894</nct_id>
  </id_info>
  <brief_title>A Clinical Pharmacology Trial of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia</brief_title>
  <official_title>A Multicenter, Open-label, Clinical Pharmacology Trial to Determine the Pharmacokinetics, Tolerability, and Safety of Brexpiprazole Long Acting Injectable (LAI) Administered as a Single Dose in Patients With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the pharmacokinetics (PK), tolerability and safety&#xD;
      of brexpiprazole LAI following a single administration in subjects with schizophrenia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentrations of brexpiprazole</measure>
    <time_frame>Blood Sampling for plasma drug measurement Day 1 (predose and 4, 8, 12 hours postdose), 2, 3, 5,7,9,11,13,15,17,19, 21, 25, 28, 35, 42, 49, 56, 63, 70, 77, 84, 91, 98, 112, 126, 154, 182</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Brexpiprazole LAI: Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole LAI: Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole LAI: Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Brexpiprazole LAI: Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole LAI: Dose 1</intervention_name>
    <description>Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1</description>
    <arm_group_label>Brexpiprazole LAI: Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole LAI: Dose 2</intervention_name>
    <description>Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2</description>
    <arm_group_label>Brexpiprazole LAI: Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole LAI: Dose 3</intervention_name>
    <description>Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3</description>
    <arm_group_label>Brexpiprazole LAI: Dose 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brexpiprazole LAI: Dose 4</intervention_name>
    <description>Cohort 4: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 4</description>
    <arm_group_label>Brexpiprazole LAI: Dose 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Japanese patients who are between 18 and 64 years of age, inclusive, at the time of&#xD;
             informed consent&#xD;
&#xD;
          -  Patients with a diagnosis of schizophrenia as defined by the DSM-5速 criteria&#xD;
&#xD;
          -  Patients who are able to remain at the trial site for the protocol-defined&#xD;
             hospitalization period&#xD;
&#xD;
          -  Patients with a body mass index [BMI = body weight (kg) / height (m)2] of no less than&#xD;
             18.5 kg/m2 and less than 35.0 kg/m2 at screening&#xD;
&#xD;
          -  Patients who are able to provide written informed consent (if the patient is a minor&#xD;
             or is hospitalized for medical protection, his or her legally acceptable&#xD;
             representative must also give informed consent) prior to commencement of any trial&#xD;
             procedure and are judged by the investigator or subinvestigator to be able to meet all&#xD;
             protocol-defined requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of a concurrent mental disorder besides schizophrenia (eg,&#xD;
             schizoaffective disorder, major depressive disorder, bipolar I disorder, bipolar II&#xD;
             disorder, general anxiety disorder, obsessive-compulsive disorder, post-traumatic&#xD;
             stress disorder, dementia or mild neurocognitive disorder, and personality disorder)&#xD;
             as defined by the DSM-5速 criteria. However, this exclusion does not apply to caffeine-&#xD;
             or tobacco-related disorders.&#xD;
&#xD;
          -  Patients who fail to meet the mandatory washout periods for the prohibited concomitant&#xD;
             drugs and foods before commencement of IMP administration, or patients who are&#xD;
             anticipated to take any of the drugs or foods during the trial period&#xD;
&#xD;
          -  Patients who have received electroconvulsive therapy (ECT) within 60 days prior to the&#xD;
             administration of IMP&#xD;
&#xD;
          -  Patients with clinically significant nervous, hepatic, renal, metabolic, blood,&#xD;
             immune, cardiovascular, respiratory, or digestive system disorders However, such&#xD;
             patients may be enrolled if the condition is mild or well controlled and is considered&#xD;
             to not affect safety or PK evaluations.&#xD;
&#xD;
          -  Patients who have met the DSM-5速 diagnostic criteria for substance-related or&#xD;
             addictive disorder, including alcohol and benzodiazepines but excluding caffeine and&#xD;
             tobacco, within 180 days prior to the administration of IMP&#xD;
&#xD;
          -  Patients with a positive drug test at screening (according to the results from the&#xD;
             central laboratory). However, such patients may be enrolled if their condition is not&#xD;
             diagnosed as a substance-related or addictive disorder, according to the DSM-5速&#xD;
             diagnostic criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehisa Matsumaru</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Kuramitsu Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brexpiprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

